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Chimeric antigen receptor T cells (CAR T cells) are dosed similarly to donor lymphocyte infusions 
following hematopoietic cell transplantation. In this perspective paper a mathematical basis for personalized 
dosing of CAR T cells is introduced. 
~~~~~~~~~~~~~ 
 
Chimeric antigen receptor T cells (CAR-T cells) are genetically engineered T cells transduced with an 
antibody-like cell surface antigen-binding domain (single chain variable factor, scFv) combined with T cell 
activating domains. 1 2 3 CAR-T cells are highly active against lymphoid malignancies such as acute 
lymphoblastic leukemia (ALL), non Hodgkins lymphoma (NHL) and multiple myeloma, which express cell 
surface antigens such as CD19, CD22 and BCMA, mounting a proliferative response with cytotoxicity and 
clearance of the antigen bearing tumor. 4 This therapy is complicated by severe toxicity, specifically cytokine 
release syndrome and neurotoxicity. The factors impacting toxicity include CAR T cell dose, tumor burden 
and potentially T cell subtypes infused. 5 6 CAR T cell dosing in most trials to date is similar to donor 
lymphocyte infusion (DLI) dosing following allogeneic hematopoietic cell transplantation (HCT). This 
dosing schema fails to take into account the unique mechanism of action of CAR T cells, i.e. the 
relationship between the antigen and transduced, antigen-binding domain driving T cell proliferation and 
function.     
To understand the principle behind DLI dosing, the dynamics of alloreactive T cell responses observed 
following HCT needs to be understood. The alloreactive donor T cell response in graft-versus-host-diseases 
(GVHD), is a considerably more complex problem than that of single antigen directed CAR T cell response 
kinetics. Lymphocyte and T cell proliferation kinetics post HCT demonstrate the following principle 
features; (a), lymphocytes and T cells follow logistic growth kinetics, with exponential growth and eventual 
plateau, 7 and (b), T cell clonal repertoire is complex and has a Power law distribution which is maintained 
after HCT. 8 Based on these findings, whole exome sequencing of HCT donors and recipients was done 
and identified a multitude of recipient specific polymorphisms, 9 which may yield a large library of 
potentially alloreactive HLA binding peptides. 10 The distribution of peptide antigen binding affinity to 
HLA molecules compliments the T cell repertoire in each individual, and as such alloreactive donor T cell 
repertoire may be simulated if the binding affinities and antigen expression levels are known. 11 12 These 
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simulations rely on unique T cell clones growing in proportion to the binding affinity of the target 
alloreactive peptide to the HLA molecule, the affinity of the T cell receptor for the HLA-bound peptide 
antigen, and the expression levels of the protein from which the peptides are derived. The resulting 
simulations reproduce patterns seen in clinically observed T cell repertoire. 11 12 
The principles of antigen-driven T cell proliferative response may be applied to CAR T cells as well; these 
cells respond to a specific antigen and grow exponentially reaching a peak and then eventually settle to a 
steady state population in most responding patients. 13 Similar to the case for alloreactive T cell 
proliferation presented above, the magnitude of the peak response and plateau is likely proportional to the 
CAR specific antigen expression level (CD19, CD22, BCMA etc.) and the binding affinity of the scFv 
domain of the CAR construct for the epitope in question, as well as the second signal domain/s included 
in the CAR construct. 14 15 Heterogeneity introduced by different binding affinities of the CAR constructs, 
as well as the target antigen-cell surface expression may result in variable efficacy/toxicity profiles observed 
with various CAR T cell products, assuming that the toxicity is related to uncontrolled proliferation of 
CAR T cells and ensuing cytokine storm. Using the above principles T cell proliferation may be modelled 
as a function of time.  
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In this iterating equation the number of CAR-T cells at the beginning of the interaction (time 0) is given as 
N0 (CART) (1 in this equation), and the number at time, t is given by Nt (CART), and for the preceding 
iteration/time by Nt-1 (CART), and the final steady state level is given by K (CART). The growth rate of CAR-T cells 
is given by r and the binding affinity of the scFv construct and the antigenic epitope is denoted by B. The 
term P is a multiplier for K and denotes the level of antigen/malignant cell burden in question, with 
growth rate q. The term e(q-r)t computes the change in malignant cell population relative to CAR T cell 
growth, where if the CAR T cell growth rate r is higher than the growth rate q of the malignant cell 
population, this term declines and vice versa; the term 1 in this expression accounts for the CAR T cell 
persistence after the malignant cell burden has been eliminated.  CAR T cell growth rate when calculated 
using equation 1 yields the familiar CAR T cell growth response curve (Figures 1 & 2). 16 17 18 19   
With appropriate parametrization, such a model may be used to establish safe dosing nomograms which 
allow for the anti-tumor effect of the CAR T cells, to be established while minimizing toxicity making this 
approach superior to trial and error, phase I type studies. This would require calculating the precise antigen 
driven CAR T cell proliferation.  Consider a simple acute lymphoblastic leukemia (ALL) model; assuming 
an equilibrium between the malignant cells infiltrating the bone marrow space and in circulation, we may 
assume that the post infusion CAR T cell population present in blood would be proportional to that 
present in the marrow, and the circulating CAR T cell numbers would quantitatively reflect the total 
pool. If the CAR-Ag binding affinity is known, plotting the CAR T cell numbers in blood following an 
infusion as a function of time by taking repeated measures would allow correlation with disease burden. 
The CAR T cell growth over time curve and the resulting rate of growth may be correlated with 
tumor/antigen burden. In such calculations, one may derive a continuous variable representing antigen 
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burden (proportional to tumor load and antigen expression), by determining the absolute blast count in 
circulation, and in the bone marrow space taking into account cellularity and tumor infiltration expressed 
as fractions and assuming uniform involvement. Correlation of the rate of CAR T cell growth with antigen 
burden, and with known CAR-Ag affinity will allow the establishment of dose-response curves for various 
products. Similar consideration may be applied to studying dose-toxicity relationships with cytokine release 
syndrome (CRS) and neurotoxicity. Furthermore, unlike DLI where following infusion a mandatory period 
of several weeks has to elapse before a second infusion may be administered because of concerns for 
GVHD, such concern does not exist from CAR T cells. This would allow clinical trial to be designed in 
which multiple low-dose CAR T cell infusions may be tested.  
Current CAR T cell dose determining studies are being designed as traditional phase I trials, using cell 
doses based on donor lymphocyte infusion (DLI) dosing schema. 20 While these have allowed gradual 
improvement in clinical outcomes, they do not lend themselves to personalized dose determination. These 
designs are inherently flawed, because CAR T cell and DLI are not comparable therapeutic modalities. 
With DLI, a multitude of donor T cell clones is infused into the recipient with the expectation that the 
cognate alloreactive/tumor specific antigen will be present and increasing DLI cell dose will stochastically 
improve the odds of encountering tumor specific antigens whilst avoiding simultaneously presented normal 
host antigens. Equation 1 for multiclonal T cells takes the form, 12 
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Equation 2, while similar to equation 1, now depicts the growth of a single, ith T cell clone, when its T cell 
receptor (TCR) with affinity Zi, ligates the jth peptide bound to an HLA molecule (with an affinity Bj). 
Critically, Pj in this instance depicts the tissue expression of the protein from which the jth peptide is 
derived, and the cell mass which expresses this protein. This is a significantly smaller value, compared to an 
epitope on a surface expressed protein which is directly recognized by a CAR, and results in a significantly 
smaller K for individual T cell clones when compared to CAR T cells. This is because CAR T antigens are 
expressed at several fold higher levels and available for interactions with CAR T cells, than are HLA-bound-
peptides for TCR. Furthermore, the likelihood that tumor associated peptides, and alloreactive peptides 
will be presented is significantly lower because of the myriad of peptides presented by HLA (Figure 3A). 
This will render the likelihood of a GVHD-free therapeutic response to DLI, a probability function of the 
presence of relevant T cell clones (rT) in the DLI and presentation of the target antigen (rP) to these 
clones. The probability of an antitumor response to the DLI (rR) will in this event be,  𝜌𝑅 = 	𝜌𝑃. 𝜌𝑇 
As an example, one may consider that rT is proportional to the T cell dose infused with the DLI, and is, for 
example 20% in the lowest dose level of the DLI. If one were to then estimate the rP to be 20% as it 
competes with normal tissue peptides also being presented on HLA, the likelihood of a therapeutic 
response to DLI (without GVHD) will be approximately 4% and will go up with subsequent infusions. 
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Most other anti-tumor responses will be associated with GVHD. This value is significantly lower than the 
essentially 100% likelihood of a CAR T cell response (Figure 3B).   
In short, unlike DLI, CAR T cells have definite targets generally with high expression, and unlike drugs, 
these cells grow in response to their target, and this proliferation is proportional to the antigen burden and 
CAR construct binding affinity. Therefore, CAR T cell dosing needs to account for tumor burden and will 
in most instances, be a relatively low number of CAR T cells infused to achieve the desired 
target. Mathematical modelling of the relationship between tumor burden and CAR T cell expansion for 
various products, may allow for the optimal individualized dosing of CAR T cells for patients.  
~~~~~~~~~~~~ 
Figure 1. Hypothetical CAR T cell growth kinetics. A. Equation 1 solved with the growth rates, r and q set 
at 1.5 and 1.2 respectively and B chosen arbitrarily (1/IC50, CD19-CAR ScFv IC50 =1.6 nM). N0 (CART) is 1, 
and the constants P and K are 1000 & 1000000 respectively. Initial exponential expansion, followed by 
steady state CAR T cell population is seen, latter corresponding to a memory T cell population once 
cytoreduction has occurred.  
 
Figure 2. CAR-T cell expansion (black line) and corresponding ALL blast count (red line) decline on 
logarithmic scale (natural log base 2.7182).    
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Figure 3. T cell proliferation kinetics. A. HLA-dependent presentation of tumor associated 
peptides (red) and expansion of donor T cells (green TCR) in response to antigens. There is 
competing expansion of other non-tumor associated antigen (grey) responsive T cell clones (blue 
TCR). B. HLA independent expansion of CAR-T cells in response to epitopes on tumor targets. 
A. 
 
 
B.  
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